Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Zambia Ivermectin Trial for COVID-19
NCT04891250Phase 4Withdrawn
- Sponsor
- Center for Infectious Disease Research in Zambia
- Start
- Oct 2021
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of ivermectin in coronavirus disease 2019 (COVID-19) (4 arms), sponsored by Center for Infectious Disease Research in Zambia. Primary endpoints: All-cause COVID-19 related mortality at 28 days and COVID-19 Infection. Planned start Oct 2021; status: withdrawn.
02
Drugs
ivermectin
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04891250.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04891250.